What Is IGF-1 LR3? Definition and What Research Reports

Plain-language definition

IGF-1 LR3 — usually written out as Long R3 insulin-like growth factor-1 — is a modified, laboratory-produced version of a natural human hormone called insulin-like growth factor 1 (IGF-1). Natural IGF-1 circulates almost entirely bound to carrier proteins that limit how much of it can reach a receptor at any moment. The LR3 version was engineered so that it sticks to those carrier proteins much less, which is why it behaves as a more persistently available form of the molecule in a test tube or a culture dish. In practice the term is most often encountered in two very different places: on the label of a cell-culture supplement used in biotechnology, and in peptide discussion forums where the compound is talked about far beyond anything the published literature has tested.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, symptom or substance. Nothing here describes how the compound is used, and no protocol, schedule or quantity is suggested.

What IGF-1 LR3 is in biochemical terms

Human IGF-1 is a single-chain, 70-amino-acid polypeptide with structural similarity to proinsulin. It signals mainly through the IGF-1 receptor, a tyrosine-kinase receptor closely related to the insulin receptor, and its availability is regulated by a family of six IGF-binding proteins (IGFBPs) that sequester it in the circulation.

The LR3 analogue differs from the native molecule in two described ways:

• An arginine substitution at position 3 — the "R3" in the name — replacing the glutamate residue found in native IGF-1.
• A 13-amino-acid N-terminal extension — the "Long" in the name — giving a chain of 83 residues rather than 70.

Together these modifications are described in the literature as markedly reducing binding to IGFBPs while retaining affinity for the IGF-1 receptor. That combination is precisely why the analogue became a standard reagent: in serum-containing media or in a living animal, native IGF-1 is rapidly mopped up by binding proteins, whereas the LR3 form is not to the same extent.

How it is produced

IGF-1 and its LR3 analogue are recombinant proteins, not synthetic peptides assembled residue by residue, and their manufacture is itself an active research topic. A 2023 report in Applied Microbiology and Biotechnology described recombinant expression of both IGF-1 and LR3 IGF-1 as fusion constructs with xylanase in the yeast Pichia pastoris, an approach the researchers used to improve secretion and recovery of the growth factor (PMID 37261455). The study is a useful reminder that product identity and purity depend entirely on the expression system and downstream processing, which differ between suppliers and are not standardised outside regulated manufacturing.

How the term is used in peptide research

In legitimate laboratory use, IGF-1 LR3 appears chiefly as:

• a cell-culture supplement, where its resistance to binding proteins makes it more potent and more stable than native IGF-1 in serum-free or serum-reduced media, including in industrial mammalian-cell bioprocessing;
• an experimental probe of IGF-1 receptor signalling in animal models, where investigators want receptor stimulation without the confounding influence of IGFBP sequestration;
• a reference or comparator protein in expression and purification work, as in the yeast fusion study above (PMID 37261455).

Material sold for these purposes is labelled research use only (RUO). RUO products are not approved medicines, are not manufactured to pharmaceutical standards, and carry no human safety or efficacy evaluation. Separately, recombinant human IGF-1 (mecasermin) exists as an approved prescription product for specific, rare growth-hormone-axis disorders — but mecasermin is native-sequence IGF-1, not the LR3 analogue, and the two should not be treated as interchangeable.

Where the term is misused

Several recurring errors show up when the term leaves the laboratory:

1. Treating in-vitro potency as a whole-body claim. Greater activity in a culture dish, where binding proteins are the limiting factor, does not translate into a predictable effect in an intact organism with intact feedback loops.
2. Confusing IGF-1 LR3 with IGF-1 itself, with Des(1-3) IGF-1, or with "MGF". These are distinct molecules with distinct binding behaviour.
3. Assuming receptor stimulation equals tissue growth. Published animal work has not borne this out consistently; the fetal sheep study below reported no growth promotion (PMID 39679943).
4. Citing bodybuilding anecdote as evidence. There is no controlled human trial literature for the LR3 analogue of the kind that would support any performance or body-composition claim.

Related terms

What the published literature reports

Fetal growth models

A 2025 study in the American Journal of Physiology — Endocrinology and Metabolism examined IGF-1 LR3 in late-gestation growth-restricted fetal sheep. The researchers reported that IGF-1 LR3 did not promote growth in that model — a negative finding directly contradicting the assumption that an IGFBP-resistant analogue will reliably drive anabolism in a growth-limited setting (PMID 39679943).

Insulin secretion

An earlier report in the Journal of Developmental Origins of Health and Disease (2023) examined an acute IGF-1 LR3 infusion in fetal sheep and reported attenuated glucose-stimulated insulin secretion during the infusion. The study further reported that this attenuation did not persist when islets were subsequently isolated and tested, suggesting the effect reflected the in-vivo environment rather than a lasting change in the islets themselves (PMID 37114757). Because IGF-1 signalling overlaps with insulin signalling, interactions with glucose handling are a recurring theme in this literature.

Neurodegeneration model

A 2025 paper in the Journal of Alzheimer's Disease tested intranasal Long R3 IGF-1 in male 5XFAD mice, a transgenic amyloid model. The researchers reported that the treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283). That dissociation — a biomarker moved, behaviour did not — is a classic illustration of why surrogate endpoints are treated cautiously.

Manufacturing and reagent science

The yeast expression work described above remains the most recent published account of how the analogue itself is made, using xylanase fusion in Pichia pastoris to express IGF-1 and LR3 IGF-1 (PMID 37261455).

Tolerability findings in animal studies: What Studies Report

The verified literature summarised here was not designed as safety testing, and none of it was conducted in humans. The physiological signal most relevant to caution is metabolic: researchers reported attenuated glucose-stimulated insulin secretion during acute infusion in the fetal sheep model (PMID 37114757). Beyond that, the growth study in growth-restricted fetal sheep reported an absence of the expected growth effect rather than a defined toxicity (PMID 39679943), and the murine intranasal study reported a change in cortical plaque architecture without cognitive preservation (PMID 39610283). No human adverse-event profile for IGF-1 LR3 exists in this evidence set.

Limits of the evidence

• The published work is animal and in-vitro: sheep fetuses, transgenic mice, yeast expression systems.
• Routes and models differ widely (infusion into a fetus, intranasal delivery in mice), so results do not generalise across contexts.
• Two of the four studies reported negative or dissociated outcomes, which is important context against promotional framing.
• Reagent-grade material is unstandardised; identity and purity depend on the expression and purification route (PMID 37261455).

References

• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology: Endocrinology and Metabolism, 2025)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)